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ABSTRACT
Ye, Qinmao, M.S. Department of Pharmacology and Toxicology, Wright State
University, 2018. Exosomes Released from Multiple Myeloma Cells Influence the
Angiogenic Function of Endothelial cells By Regulating MicroRNA-29b

Multiple myeloma is a hematological malignancy characterized by clonal
proliferation of plasma cells generally caused by chromosomal abnormalities. It occurs
in the bone marrow, which is the microenvironment of multiple myeloma. Exosomes
(EXs) are 30-100 nm membrane-derived micro-vesicles containing various of bioactive
molecules, such as microRNAs, to mediate the cell-cell interaction. Numerous studies
reported that exosomes play a significant role in tumor microenvironment.
Angiogenesis has the important implication in tumor exacerbation to supply nutrients
to promote the progression of cancer cells through endothelial cells (ECs). Some studies
demonstrated that microRNA-29b (miR-29b) can suppress tumor development and
inhibit angiogenesis. Therefore, in this study, we designed experiments to research the
relationship between exosomes released from multiple myeloma, miR-29b and
angiogenesis in ECs. Two types of multiple myeloma cells, OPM2 and RPMI-8226 cell
lines, were treated with C6-Ceramide. Their released exosomes (MM-EXC6-Cer) were
collected, which enriched in miR-29b. MM-EXC6-Cer were cocultured with human
umbilical vein endothelial cells (HUVECs) to test the effect on angiogenic function of

iii

HUVEC. The results showed that the EC proliferation, the tube formation, migration
and vascular endothelial growth factor A (VEGFA) expression were decreased in ECs.
In addition, miR-29b inhibitor was used in ECs, and could decrease the level of the
miR-29b in ECs. Exosomes released from multiple myeloma cells (MM-EX) were
cocultured with ECs, which were treated with miR-29b inhibitor, to examine the effects
on EC angiogenic function. We found that EC proliferation, VEGFA expression,
migration and tube formation were promoted. This data demonstrated that miR-29b can
negatively modulate the angiogenic function of ECs through exosomes secreted by
multiple myeloma cells.
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Ⅰ. INTRODUCTION

Multiple Myeloma
Multiple Myeloma (MM) is a deadly hematological malignancy

[1]

. It is

characterized by the clonal proliferation of plasma cells in the bone marrow (BM), and
a monoclonal protein existing in the serum or urine [2].
MM accounts for approximately 13% of hematologic cancers [2], but it has nearly
20% deaths of hematological malignancy [3]. MM was first time to be documented in
1844. In the next period, it is gradually descripted detailly, and the new treatment are
continuously discovered. MM diagnosed in Africa and America is 10-12/100,000, and
it is in Asia is 0.5-1/100,000

[4]

. Most of patients are approximately 70 years old, and

37% of patients are younger than 65 years old [2].

Chromosomal Abnormalities in MM
There are some factors to arouse MM, such as obesity, family history, genetic
factors and even environmental factors. In general, MM is most thought to be preceded
by a monoclonal gammopathy of undetermined clinical significance (MGUS), and
process to malignant MM [5]. DNA damage occur in malignant plasma cells during the
process of MM pathogenesis [2]. Aneuploidy is a common finding in MM.
The

primary

chromosomal

abnormalities
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are

typically

involved

the

immunoglobulin heavy chain (IgH) that switch region on chromosome 11 and 14. The
secondary translocations are usually discovered during tumor progression, and there are
four abnormalities often reported [1] (Table 1). Chromosomal abnormalities can activate
proto-oncogenes or inactive tumor suppressor gene inactivation

[6]

, and they also

correspond to stimulation in MM microenvironment [2].

Table 1. Chromosomal Translocations in MM

Table 1. Chromosomal Translocations in MM
Location

Development of MM

t (11:14) (q13; q32)

Most

Common

[7-9]

Abnormality;

Chromosomal

Involves bcl-1 Oncogene;
Found in 15% Patients;
Associated with a Favorable Outcome

Primary
Translocations

t (4:14) (p16; q32)

Involves

Wolf-Hirschhorn

syndrome

[10-13]

candidate 1 gene (WHSC1) & fibroblast
growth factor receptor 3 (FGFR3);
Poor Survival

t (14:16) (q32; q23)

Less

Common,

but

significant

[9,10]

importance in clinical process;
Juxtaposes IgH locus and c-MAF locus;
Poor Outcome
Involve in 45% of the patients;

MYC Oncogene &

Late-Stage events in tumor progression

Ig Locus (8q24)
(Bergsagel and Kuehl, 2001;
Gabrea et al., 2008)
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Found in 50% of patients;

Deletion of

Close Associated with the translocation t

Chromosome 13

Secondary

(4：14) (p16; q32)

[9] [13,14]

Rare in Late-Stage events;

Deletion of 17p13

Translocations

Reported in 10% of patients;

[15,16]

Correlation with a Poorer Outcome
Deletion generally to 1p;

Chromosome 1

Amplifications correspond to 1q

[8,9] [17,18]

The Microenvironment of MM
The BM as the microenvironment of MM exerts a significantly important effect on
cell proliferation, growth and survival of MM cells

[19]

. Bone cells, myeloma cells,

endothelial cells and extracellular matrix take close interactions in this
microenvironment. MM cells adhere to bone marrow stromal cells (BMSCs) to
maintain cell proliferation and invasion [20].
Certain proteins in extracellular matrix can mediate via cell receptors to induce
tumor cells growth, such as vascular endothelial growth factor (VEGF), interleukin-6
(IL-6) [21], insulin-like growth factor 1, tumor necrosis factor and transforming growth
factor ꞵ1. The involvement of IL-6 enhances the adhesion of multiple myeloma cells to
promote cell survival in BM

[1]

. These proteins are produced and secreted by cells,

including myeloma cells, to the BM to influence the microenvironment of MM.
Exosomes are novel sight in tumor microenvironment that are thought to mediate
the cell-cell interactions in MM microenvironment. BMSCs derived Exosomes directly
facilitate MM progression

[22,23]

. Exosomes released from MM cells regulate the BM
3

microenvironment via enhancing the angiogenesis and immunosuppression [19]. Nucleic
acids also play an important role in the microenvironment of MM through Exosomes.
Exosomes carry nucleic acids, such as microRNAs, mRNAs, long non-coding RNAs,
DNA fragments

triggering

significant

phenotypic

changes

in

the

tumor

microenvironment [24].

Angiogenesis in MM
Angiogenesis is a process that new vessels are generated from existed vasculature
[25]

. Some studies reported that angiogenesis is regulated by molecules and micro-

vesicles. At meanwhile, angiogenesis plays a significantly role in tumor progression,
which can supply nutrients and growth factor to promote the development of tumor
cells [25]. In the microenvironment of MM, cell-cell interaction promotes the production
of growth factors, such as VEGF, which up-regulates the angiogenesis in MM [2].

Exosomes (EXs)
EXs are 30-100 nm membrane-derived vesicles that contain a wide range of
functional proteins, lipids, mRNAs, and microRNAs to mediate the cell-cell
communications. They usually present in blood, urine, breast milk and semen.
Numerous studies identified that various cell types can release EXs including immune
cells, tumor cells, endothelial cells, stem cells and among others [25]. CD9, CD81, and
CD63 are classic exosomal markers [26] carried by EXs.
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It is reported that EXs fused with the recipient cells membrane are more likely to
occur in the acidic extracellular environment [27]. Depend on the parental cells of EXs,
they can play a variety of specific role with carried different nucleic acids, proteins or
lipids. For instance, when EXs released from tumor cells, the content of EXs promote
angiogenesis and cell proliferation

[28]

. If EXs secreted from immune cells, they can

assist in antigen presentation [29]. Otherwise, EXs can travel to distant cells to have
effects via body fluids

[30]

. Recently, tumor-derived EXs are thought as the potential

vaccines for the tumor [31], and they have potential diagnostic abilities in cancer disease
[32]

.

The Biogenesis of EXs
The biogenesis of EXs starts with endocytosis that are from the inward budding of
plasma membrane to form the early endosomes

[33]

. Early endosomes mature to late

endosome, which is also known as multivesicular bodies (MVBs). In this process,
intraluminal vesicles (ILVs) are accumulated inside of MVBs through the endosomal
sorting complex required for transport (ESCRT) machinery
independent pathways, such as ceramide-dependent mechanism

[34]

[35]

and ESCRT-

(Table 2). EXs

secreted by MVBs fusing with the plasma membrane to release ILVs to extracellular
space, which are referred to EXs. MVBs can fuse with lysosomes to degrade content
[33]

(Figure 1).

5

Figure 1. The Biogenesis of EXs and MVBs

Table 2. The Mechanism of EXs Generation

Table 2. The Mechanism of EXs Generation [36,37]

ESCRT Pathway

Type

Functions

ESCRT-0

Cluster cargo in a ubiquitin-dependent way

ESCRT-Ⅰ

Involve in budding

ESCRT-Ⅱ
ESCRT-Ⅲ Vesicle scission

ESCRT Independent
Pathway

Involve lipids (ceramide, cholesterol,
phospholipase D2), or tetraspanins

MM Derived EXs
EXs released from tumor cells have been identified that MHC class Ⅰ molecules is
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loaded in EXs [38]. MM derived EXs (MM-EX) also have the same characterization.
MHC class Ⅰ, CD44 and bone marrow stromal antigen 2 (BST-2) are rich in the
membrane of MM-EX. Moreover, antigen presenting molecules, adhesion molecules,
membrane transport, cytoskeletal proteins and other bioactive proteins play important
roles in development of MM from MM-EX [39].
It has been reported that EXs released from MM cells can promote angiogenesis
in BM to enhance MM growth [40]. MM cells produced EXs with the hypoxia
conditions can increase the endothelial tube formation through HIF-FIH signaling
pathway [41]. MM-EX also play a role in enhancement the osteoclastic activity in the
BM [42], and it induces osteoclast precursors to differentiate to osteoclasts [43]. Of note,
EXs secreted from MM can directly increase MM cell proliferation [44].

EXs in Angiogenesis
EXs have been indicated that exert salutary or deleterious effects on angiogenesis
due to their different content or origins [25].
The function of EXs secreted from tumor cells are also high-profile. The support
of numerous blood vessels is necessary to cancer exacerbation, which can supply
nutrients and growth factors to tumor. EXs from chronic myeloid leukemia cells affect
vascular remodeling via IL-8 activated VCAM-1 [45]. There are other studies that
identify that EXs released from tumor cells influence enhancement in angiogenesis.
Moreover, EXs are thought as a new therapeutic target for the treatment of certain
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tumor.
Endothelial cells (EC) derived EXs play potential roles in regulation the autocrine
or paracrine factors via proteins and RNAs/microRNAs. MicroRNA-146a-laded
exosomes released from ECs cocultured with cardiomyocytes leading to a decrease in
metabolic activity [46]. However, it is also reported that endothelial exosomes promote
capillary-like structure formation for neighboring ECs through the Delta like
ligand/Notch pathway [47].
In addition, EXs generated from platelets, stem cells, and cardiomyocyte cells are
reported that they have pro- or anti- effects in angiogenesis [25].

MicroRNAs
MicroRNA (miR) is approximately 22-nt-long non-coding RNA molecules,
which regulates the activity of specific mRNA targets. It exerts functions on cell
proliferation, inflammation, angiogenesis, apoptosis and oncogenesis [48]. MiRs are
widely found in animal, plants and unicellular eukaryotes [49].
MiRNAs play function through the RNA-induce silencing complex (RISC),
which is mature miR loaded into the ribonucleoprotein complex. RISC specifically
bind in the specific 3’-untranslated regions (3’-UTR) of the target genes to inhibit
translation or degrade mRNA [48].
MiRs are potentially involved in MM as oncogenes or tumor suppressors through
signaling pathways [50].
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The Biogenesis of Human MiRs
Human miRNA biogenesis is briefly formed through two-step cleavage events by
two ribonuclease Ⅲ endonucleases, Drosha and Dicer, respectively performed in
nuclear and cytoplasm [51].
MiRs are transcribed by RNA polymerase Ⅱ or Ⅲ to produce primary miRNA
(pri-miRNA) molecule. Following Drosha-DGCR8 complex process the pri-miRNA
into approximately 70-nucleotide precursor miRNA (pre-miRNA). The pre-miRNA is
then exported to the cytoplasm via RAN-GTP and Exportin-5, and it is next cleaved
by Dicer, assisted by TRBP, to the ~22 nt miRNA duplex containing mature miRNA
[52]

(Figure 2).

Figure 2. The Biogenesis of Human MiRs
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EXs-derived MiRs
EXs, as the delivery tool in vivo, can contain functional miRs to exert effects.
According to the biogenesis of EXs, the components of EXs form in the MVBs before
they secreted rom parental cells. Therefore, the mature miRs are loaded into EXs in
this process. Some studies reported that miR sorts into EXs through a ceramidedependent secretory mechanism [53]. Also, the miR loaded into EXs is probably in a
miR-induced silencing complex independent manner [54]. Interestingly, EXs-derived
miRs do not completely copy from parent cells, suggesting that miRs are selectively
packed into EXs [55,56].
It has been indicated EXs-derived miRs regulate the recipient cell migration,
inflammation, immune responses, angiogenesis and metastasis [48]. In addition, miRs
in EXs released from tumor cells play dual roles in tumor progression. Numerous
studies demonstrated that exosomal miRs can be used as diagnostic biomarker. Luo et
al [57] reported that EXs-derived miRs can serve as biomarkers in pregnancy disorders.

MiR-29b
MiR-29b has two sub-family members – miR-29b1 and miR-29b2. These two
types of miR-29b come from two different per-miRNA, but the mature miR-29bs are
identical [58]. Many studies have indicated that miR-29b can serve as a tumor
suppressor [59]. In MM, miR-29b negatively modulates the migration of MM and ECs
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[60]

. In breast cancer, miR-29b is involved in angiogenesis, and targets VEGFA in this

microenvironment [61].
Cheng et al measured the miR-29b levels of exosomes released from MM cells
treated with C6-ceramide (MM-EXC6-Cer) and found that miR-29b expression were
significantly increased (Figure 3). Also, Cheng et al examined the proliferation of
MM cells after cocultured with MM-EXC6-Cer and found that the MM cell proliferation
was remarkably inhibited [62].

Figure 3. The MiR-29b Expression in MM-EXs with Different Condition.
The miR-29b level in MM-EXC6-Cer was significantly increased compared to MMEXControl and MM-EXGW4869.

11

Ⅱ. HYPOTHESIS AND SPEICIFIC AIMS

Hypothesis:
The angiogenic function of ECs is partially regulated by miR-29b with the MMEX.

Specific Aims:
Aim 1: to determine the effects of exosomes derived from C6-Ceramide stimulated
multiple myeloma cells (MM-EXC6-Cer) on ECs angiogenic function (migration, tube
formation ability and VEGFA expression), and the levels of miR-29b in ECs.

Aim 2: to determine the role of miR-29b in mediating the angiogenic function of
MM-EX on ECs.
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Ⅲ. EXPERIMENTAL DESIGN

Design for Specific Aim 1:
Two types of MM cell lines, OPM2 and RPMI-8226, were used in this study.
Each cell lines were respectively cultured in serum-free medium (Vehicle group) and
in 10 μM/μl C6-ceramide serum-free medium (C6-Cer group) for 48 hours. Culture
media samples were collected for EXs isolation. MM-EXveh and MM-EXC6-cer were
respectively suspended in HUVEC completed media, and then cocultured with ECs in
48 hours to examine the EC proliferation, tube formation, migration and VEGFA
expression (Figure 4).

Figure 4. The Flow Chart of Experimental Design 1
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Design for Specific Aim 2:
MiR-29b inhibitor and miRs inhibitor control were respectively transfected into
ECs for 6 hours in advance. All MM cells were cultured in serum-free media for 48
hours; the cell supernatant was then used for EXs isolation. Then EXs were suspended
with HUVEC completed media to be cocultured with ECs for 48 hours to test the cell
proliferation, tube formation, cell migration and VEGFA expression of ECs (Figure
5).

Figure 5. The Flow Chart of Experimental Design 2
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Ⅳ. MATERIALS AND METHODS

Materials
OPM2 MM cell lines was a gift by Dr. Zhan (University of Iowa). RPMI-8226
cell lines, HUVEC lines and F-12K medium for HUVEC were purchased from ATCC
company. RPMI 1640-medium for MM cells and fetal bovine serum (FBS) were
purchase from Hyclone Corp. Endothelial cell supplement factor, heparin for cell
culture, antibiotic-antimycotic solution, trypsin, methylthiazolyl tetrazolium (MTT),
antibodies for western blotting, N-Hexanoyl-D-sphingosine (C6-Ceramide) and
PKH26 were purchased from Sigma-Aldrich company. TRIzol reagent was from
Invitrogen, and Matrigel matrix was purchased from Corning company. CDNA
synthesis kit was purchased from Takara company, and q-PCR kit was from
GeneCopoeia. MiR-29b inhibitor (SiRNA-29b), miR inhibitor control, and
transfection reagent was purchased from Dharmacon company.

Methods
1.

Cell Culture
HUVECs were culture in F-12K medium with 10%fetal bovine serum (FBS),

0.05 mg/ml endothelial cell growth supplement, 0.1mg/ml heparin sodium salt from
porcine intestinal mucosa, and penicillin/streptomycin. Human MM cells line OPM2,
RPMI-8226 were culture in RPMI 1640 medium, supplemented with 10% fetal
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bovine serum and antibiotics. All of cells in this experiment were maintained at 37°C
with 5% CO2 and 95% humidity.

2.

EXs Extraction and Immunofluorescence Staining
EXs were collected from the culture supernatants of MM cells by multiple

centrifugations. Firstly, cell medium was harvested when MM cells cultured in serumfree medium in 48 hours. Then, the medium was centrifuged for 20 min at 2000g to
remove cells and cell debris. Next, the cell-free culture medium was centrifuged again
at 20,000g for 70min, and ultra-centrifuged at 170,000g for 1.5h. The pelleted EXs
were resuspended with filtered PBS or medium to be used for following experiments.

3.

Nano Tracking System Analysis (NTA)
Nano Tracking System Analysis (NTA) 300 was used to analyze the size and

concentration of these exosomes. EXs suspended in PBS were loaded into the sample
chamber. Light scatter mode of the tracking system used the camera level 10 and the
camera filter 1. 30 seconds videos were taken three times with a frame rate of 30
frames per second. NTA 3.0 software was used to analyze the data.

4.

EXs Uptaking
To examine the uptake of EXs, PKH67 was used to label EXs. 4 μl of PKH26
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with 1 ml PBS to staining every 30 μg of EXs for 4 min protected from light. Then
added an equal volume of 1% BSA to stop staining reaction, and centrifuged at
170,000g in 90 min at 4°C. Next, EXs pellet was washed with PBS and centrifuged at
170,000g for 90 min at 4°C. The EXs were resuspended with completed F-12K
medium and cultured with ECs for 24 hours. After removed the old medium,
HUVECs were washed with PBS and stained with DAPI for 5-10 minutes in room
temperature pretend from light. Then, HUVECs were washed with PBS again and
fixed with 4% formaldehyde. LSM710 laser scanning microscope was used to take
the pictures of the EXs uptake in ECs.

5.

Co-culture System
For aim 1: MM cell were respectively cultured in serum-free medium and in 10

μM/μl C6-ceramide serum-free medium for 48 hours. Culture media samples were
collected for EXs isolation. MM-EXveh and MM-EXC6-cer were respectively suspended
in HUVEC completed media, and then cocultured with ECs in 48 hours.
For Aim 2, miR-29b inhibitor and miRs inhibitor control were respectively
transfected into ECs for 6 hours in advance. All MM cells were cultured in serum-free
media for 48 hours; the cell supernatant was then used for EXs isolation. Then EXs
were suspended with HUVEC completed media to be cocultured with ECs for 48
hours.
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6.

Cell Proliferation Assay
HUVEC cell proliferation was examined by MTT assay. ECs were seeded in a

96-well plate at 1 × 103 cells in each well, and cocultured with OPM2 and RPMI8226 released exosomes for 48 hours. Then, the cells were incubated with 20μl of 5
mg/ml MTT solution for 4 h at 37°C. After removed the medium containing MTT,
150 μl dimethyl sulfoxide (DMSO) was added to each well. The microplate reader
was used to measure the optical density at 490 nm.

7.

Migration Assay
HUVECs were seeded in the 6-well plate and cultured until 90% confluent. A

1ml-pipette tip was used to make a scratch on cells and the pictures were captured by
using LSM710 laser scanning microscope. After cocultured with EXs in 37°C for 12
hours, ECs were taken pictures again at the same condition. The migration distance of
ECs wase analyzed with Image J (NIH).

8.

Tube Formation Assay
Matrigel matrix was dissolved at 4°C overnight in advance. 200 μl Matrigel was

coated each well on the 48-well plate without air bubbles and gelled in incubator for
30 min. Then, 1 × 105 HUVECs were seeded in the plate and cultured for 4 hours in
37°C. Then, LSM710 laser scanning microscope was used to take the picture of tubes
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formed by the cells. Next, the length of tubes was measured by using Image J.

9.

RNA Extraction and Quantitative Real-Time PCR Analysis (qRT-PCR)
RNA was extracted with TRIzol. Transcript cDNA synthesis kit was used to

transcribed RNA samples to cDNA. QRT-PCR was performed cDNA samples using a
Bio-Rad 96 System with GeneCopoeia qRT-PCR kit. The primers U6, miR-29b,
GAPDH, VEGFA were used in this experiment. U6 and GAPDH were used as the
control gene to calculate the expression of miR-29b and VEGFA.

10. Protein Extraction and Western Blot Analysis
Exosomal proteins and whole-cell lysates were prepared by using lysis buffer.
The concentration of protein samples is measured by protein assay, and equal amounts
of proteins samples were separated in 6%-10% sodium dodecyl sulfatepolyacrylamide gels. Proteins in gel were transferred to immobilon
polyvinyldifluoride (PVDF) membranes. Western blot analyses were performed with
mouse antibodies, anti-β-actin and VEGFA (1:500), and goat antibodies, anti-Annexin
V, anti-CD63 (1:500). The secondary antibodies were used anti-mouse and anti-goat
peroxidase-linked (1:10000). The results were visualized by ECL Prime Western
Blotting Detection Reagent.
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11. MiR-29b Inhibition
HUVECs were seeded in 6-well plates or 12-well plates with 80%-90%
confluency. Then miR-29b inhibitor and miR control (miRCtrl) respectively
transfected to ECs by using DharmaFECT 1 Transfection Reagent for 6 hours.
Transfection efficacy was examined by qRT-PCR.

12. Statistical Analysis
All experimental results were replicated at least three times. Statistical analysis
was performed by using t-test or one-way analysis of variance (ANOVA) to compare
between two or three groups. In all case, p < 0.05 was considered statistical
significant. GraphPad Prism 6.0 software was used in statistical analyses.
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Ⅴ. RESULTS

Results for Aim 1
1.

The Characterization of MM-EXs
As NTA results shown in Fig 6 (A&B), the diameter of the isolated OPM2-exo

and RPMI-8226-exo were both around 100nm. The concentration was respectively
12.47 x 106 and 13.51 x 106 particles each milliliter. To further identify the microvesicles secreted from MM cells were EXs, we measured the protein levels of
Annexin V and CD63 (Fig 6C). The data showed that the expression of Annexin V
and CD63 was much more in these micro-vesicles than in OPM2 and RMPI-8226 cell
themselves.
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Figure 6. The characterization of EXs released from MM cells.
A), B) Exosomes respectively isolated the culture medium from OPM2 cell lines and
RPMI-8226 cell lines was analyzed by NTA. The NTA results of OPM2 and RPMI8226 derived exosomes indicated the diameter of these particles was both ~ 100 nm.
C) The Annexin V and CD63 were enriched in EXs compared to the cells.

2.

The Uptake of MM-EXs by HUVECs
MM-EXs were stained by PKH26 and suspended in HUVEC completed medium

to coculture with HUVEC for 24 hours. After old medium of HUVECs was removed,

22

ECs were stained with DAPI for 5-10 minutes in room temperature in dark. Then ECs
were washed with PBS and fixed with 4% formaldehyde. The images of the EXs
uptake were taken by using LSM710 laser scanning microscope. Figure 7 A, B
showed that MM-EXs was clustered around the nucleus of ECs.

Figure 7. The Uptake of EXs Secreted from OPM2 and RPMI-8226 cells.
A), B) Red: PKH26, EXs; Blue: DAPI, nucleus. Scale bars: 200 μm.

3.

MM-EXC6-Cer Decreased the Cell Proliferation of HUVECs
MM-EXC6-Cer were collected from OPM2 and RPMI-8226 cells treated with 10

μM/μl C6-ceramide to increase the microRNA-29b level in exosomes, and they were
cocultured with endothelial cells for 48 hours. Then, these ECs were incubated with
MTT solution for 4 h at 37°C. Next the medium containing MTT was removed and
DMSO was added to each well. In Figure 8, the EC proliferation was decreased after
ECs cocultured with MM-EXC6-Cer compared to ECs treated with MM-EXVeh
(p<0.05).
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Figure 8. The Effect of MM-EXs on EXs Proliferation.
After MM-EXC6-Cer cocultured with ECs for 48 hours, the cell proliferation was downregulated compared to the result of MM-EXVeh cocultured with ECs.

4.

MM-EXC6-Cer Inhibited the Cell Migration and Tube Formation of HUVECs
For migration assay, when ECs were cultured until 90% confluent, a 1ml-pipette

tip was used to make a scratch on cells. Then pictures were taken by laser scanning
microscope (Figure 9 A, B) at 0 hour and 12 hours. The results showed that the
migration of HUVEC was reduced after ECs cocultured with MM-EXC6-cer compared
to the HUVEC cocultured with MM-EXveh. It suggests that MM-EXC6-cer had an
inhibitory effect on the migration of HUVECs.
For tube formation, Matrigel was coated each well in plate firstly, then ECs were
cultured in this plate. MM-EXs were suspended in medium to be cultured ECs on
Matrigel for 4 hours in 37°C. LSM710 laser scanning microscope was used to take
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pictures of tubes formed by ECs. In Figure 9 C showed that the tube formation of
HUVEC was reduced after treatment with MM-EXC6-cer compared to the result
cocultured with MM-EXVeh. With the analysis of Image J (Figure 9 (D)), the result
also demonstrated that the tube length was inhibited in HUVEC cells which were
cocultured with MM-EXC6-cer (p<0.05).
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Figure 9. The Effect of MM-EXs on ECs Migration and Tube Formation.
A), B) ECs cocultured with MM-EXs for 12 hours, and the wound healing was
reduced with the treatment of MM-EXC6-Cer compared with the ECs cocultured with
MM-EXVeh. C) MM-EXs cocultured with ECs on Matrigel for 4 hours, the tube
lengths of ECs in MM-EXC6-Cer group were less than the lengths of ECs treated with
MM-EXVeh. D) The result of tube formation on ECs was analyzed by Image J, and
tube lengths were decreased in ECs cocultured with MM-EXC6-Cer.

5.

MM-EXC6-Cer Down-regulated the VEGFA Expression Level and Upregulated the miR-29b level in HUVECs
Endothelial cells were cocultured with MM-EXs for 48 hours, and the RNA and

protein in HUVEC were extracted. RNA samples were reverse transcription to
cDNAs. Then cDNAs was analyzed by qRT-PCR to measure the GAPDH, VEGFA
mRNA expression and microRNA U6, miR-29b level (Figure 10 A, D). U6 and
GAPDH were a normalization in PCR. The result (10 A) shows that VEGFA mRNA
levels in HUVEC was significantly down-regulated after MM-EXC6-Cer cocultured
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with ECs. In figure 10 D, the level of microRNA-29b was obviously up-regulated in
ECs which coculture with MM-EXC6-Cer compared to the vehicle group.
Western blotting was used to analyze the VEGFA and ꞵ-actin protein expression in
ECs. ꞵ-actin was as a standard control. In Figure 10 B, C, VEGFA expression was
inhibited in HUVEC when ECs treated with MM-EXC6-Cer compared to the expression
levels in ECs cocultured with MM-EXVeh (p<0.05).

Figure 10. The Effect of MM-EXs on VEGF Expression of ECs.
A) The mRNA expression of VEGFA in ECs was obviously decreased after HUVEC
27

treated with MM-EXC6-Cer. B), C) The protein of VEGF expression in ECs was also
down-regulated in ECs cocultured with MM-EXC6-Cer compared to the protein level in
ECs cocultured with MM-EXVeh. D) The microRNA-29b expression in HUVEC was
significantly increased after ECs cocultured with MM-EXC6-Cer compared to the miR29b levels in ECs treated with MM-EXVeh.

Results for Aim 2
1.

MiR-29b Inhibitor Down-regulated the Expression of MiR-29b in HUVECs
ECs were grown in plates to 80%-90% confluency. Then miR-29b inhibitor and

miR control (miRCtrl) were respectively transfected into ECs for 6 hours. RNA samples
were extracted from ECs. Also, RNA sample was collected from normal HUVEC to
serve as vehicle group. RNA samples were reverse transcription to cDNAs, and cDNAs
was analyzed by qRT-PCR to measure the miR-29b expression. In figure 11, the miR29b level in ECs of miR-29b inhibitor group was significantly down-regulated
compared to the miR control and vehicle group (p<0.05).
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Figure 11. MiR-29b Expression in HUVEC after using miR-29b inhibitor compared
to vehicle and miRCtrl group.
The miR-29b level in ECs was obviously reduced with the effect of miR-29b inhibitor.

2.

The Cell Proliferation of HUVECs Was Augmented in MiR-29b Inhibited
HUVECs
MM-EXs were collected from OPM2 and RPMI-8226 cells treated with serum-free

media to be cocultured with endothelial cells, which were prior respectively treated
with miRCtrl reagent and miR-29b inhibitor. Then, these ECs were incubated with MTT
solution for 4 h at 37°C. Next removed the medium containing MTT and added DMSO
to each well to read the optical density. In Figure 12, after the miR-29b was inhibited
in ECs, the EC proliferation was increased compared to ECs treated with microRNA
control. This result showed that miR-29b inhibitor promoted the proliferation of ECs
with MM-EXs (p<0.05).
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Figure 12. Cell Proliferation of ECs after MiR-29b Inhibition and MM-EXs
Cocultured.
The HUVEC proliferation was upregulated when the miR-29b was inhibited in ECs
with MM-EX cocultured.

3.

MiR-29b Inhibitor Promoted ECs Migration and Tube Formation in HUVECs
ECs were seeded in 6-well-plate to 90% confluent and were respectively treated

with miRNA control and miR-29b inhibitor. After 6 hours treatment, the old medium
was removed, and a 1ml-pipette tip was used to make a scratch on cells. Next ECs
were cocultured with MM-EXs. Then the picture were taken by using laser scanning
microscope (Figure 13 A, B) at 0 hour and 12 hours. The results describe that the
migration of HUVEC was augmented after ECs inhibited miR-29b with the influence
of MM-EXs compared to the results of HUVEC treated with miRCtrl. It means that
microRNA-29b inhibitor had a positive effect on the migration function of HUVEC
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with MM-EXs cocultured.
For tube formation, ECs were respectively treated with miRNA control and miR29b inhibitor for 6 hours. Matrigel was coated each well in plates. Then ECs, which
had been treated, were cultured in the plate. MM-EXs were suspended in medium to
be cultured with ECs on Matrigel for 4 hours in 37°C. LSM710 laser scanning
microscope was used to take picture of tubes of cells. Figure 13 C showed that the
tube formation of ECs was promoted after in miR-29b inhibited ECs with coculture of
MM-EXs compared to the ECs treated with microRNA control. With the analysis of
Image J, the summarized data (Figure 13 D) also indicated that the tube length was
increased in HUVEC cells which were treated with miR-29b inhibitor (p<0.05).
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Figure 13. The Effect of MiR-29b Inhibitor on ECs Migration and Tube Formation
with MM-EXs Coculture.
A), B) Inhibited ECs cocultured with MM-EXs for 12 hours, and the wound healing
was promoted compared with the miRNA control treated ECs after MM-EXs
cocultured. C) The tube lengths of ECs were less than the lengths of miR-29b
inhibited ECs with MM-EXs. D) Summarized data tube formation of ECs in different
groups.

32

4.

MiR-29b Inhibitor Up-regulated the VEGF Expression Level in HUVECs
ECs were respectively treated with miRNA control or miR-29b inhibitor for 6

hours. Then the old medium was removed, and ECs were covered with completed
medium in which MM-EXs were suspended. Treated ECs and MM-EXs were
cocultured for 48 hours, and RNA and protein samples in ECs were extracted.
RNA samples were reverse transcription to cDNAs. Then cDNAs was analyzed by
qRT-PCR to measure the GAPDH, VEGFA mRNA expression (Figure 14 A). GAPDH
was used to a normalize the mRNA level. The result (14 A) showed that VEGFA
mRNA expression in ECs was significantly up-regulated in miR-29b inhibitor group
compared to the level in ECs treated with microRNA control.
VEGFA protein levels in ECs were analyzed by the Western blotting. In Figure 14
B, C, VEGFA protein expression was obviously increased in HUVEC when treated
with miR-29b inhibitor compare to the level in ECs treated with miR control
(p<0.05).
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Figure 14. The Effect of MiR-29b Inhibitor on VEGFA Expression in ECs after MMEXs Coculture.
A) The mRNA expressions of VEGFA in ECs were obviously upregulated after
treated with miR-29b inhibitor. B), C) The protein levels of VEGFA in ECs were also
increased in miR-29b inhibitor treated ECs after cocultured with MM-EX compared
to the protein levels in ECs treated with miR control.
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Ⅵ. DISCUSSION

MM is one of the most common hematological malignancy in the world. Recent
research indicates that the microenvironment of MM, the BM, play a crucial role in
the development of multiple myeloma.
EXs are membrane-derived micro-vesicles, and they have been demonstrated to
play an important role in cell-cell interaction. EXs can serve as a delivery tool in vivo
to transport functional molecules to neighbor cells and even remoted cells. It has also
been found involved into cancer progression or suppression. The miRs are non-coding
small RNA molecules, and they consist of a large variety in human. MiRs can bind to
the 3’-UTR of target genes to repress translation to exert the modulate function. Of
now, numerous studies report that miRs are wrapped in exosomes to participate in
some physiological activities, such as immune reaction, tumor progression or
suppression. However, the detailed mechanisms between EXs and miRs remain
unknown.
In this study, we focused on the roles of EXs and miR-29b in MM cells
microenvironment. Some studies indicated that miR-29b can suppress tumor growth
via down-regulating angiogenesis. Amodio et al demonstrated that miR-29b targets de
novo DNA methyltransferase and represses the global DNA methylation in MM cells
[63]

. Previous study showed that C6-Ceramide stimulated MM cells derived EXs

enrich in miR-29b [62]. The miR-29b expression level in ECs after cocultured with
MM-EXC6-Cer was significantly increased (Figure 10 D) when compared to the level in
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ECs cocultured with MM-EXVeh. EC proliferation was slightly decreased (Figure 8)
after cocultured with MM-EXC6-Cer when compared to the vehicle group. Also, the
angiogenesis functions of ECs (tube formation and migration) were down-regulated
(Figure 9). VEGFA level was examined (Figure 10 A, B&C) after ECs cocultured
with MM-EXC6-Cer, and the expression was obviously inhibited. This result means the
VEGFA might be a target of miR-29b. Chen et al reported that miR-29b can target
VEGFA to negatively regulate the angiogenesis of ECs via the MAPK/ERK and
PI3K/Akt signaling pathways in endometrial carcinoma [64]. This study provides new
information for further research. It demonstrated that the angiogenic function of
HUVECs is down-regulated by MM cells derived EXs enriched miR-29b.
To deeper research, miR-29b inhibitor was used in in ECs, and the miR-29b
expression level was obviously decreased in HUVEC (Figure 11). Cheng et al
reported that miR-29b level in EXs secreted from serum-free MM cells was
appreciably less than the C6-Ceramide treated MM derived EXs [62]. In addition,
normal MM cell derived EXs have pro-angiogenesis effects in vivo [19]. MiR-29b
inhibited ECs and miRCtrl treated ECs both cocultured with normal EX released from
MM cells, the EC proliferation was increased in miR-29b inhibited ECs compared to
the control group (Figure 12), and the migration and tube formation function of ECs
were both augmented (Figure 13). The VEGFA expression in HUVEC was also upregulated in microRNA-29b inhibited ECs cocultured with MM-EX (Figure 14).
These results further confirm the role of miR-29b in mediating the angiogenesis of
MM-EX on ECs. MiR-29b inhibitor can promote the angiogenic function of HUVEC
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cocultured with MM-EX, suggesting miR-29b plays a negative role in endothelial
cells angiogenesis in multiple myeloma.
MM, as a hematological tumor, its microenvironment is more and more being
considered in research and clinical treatment. Previous studies indicated the oxygen
tension is lower in BM with the exist of MM than the normal BM. Therefore, EXs
released from MM in hypoxic condition are also valuable direction. Umezu et al
reported that exosomal miR-135b regulates the MM angiogenesis in hypoxic
condition, and miR-135b from MM derived EXs enhanced the angiogenic function of
MM [41].
Tumor microenvironment is increasingly high-profile in recent years.
Extracellular vesicles, such as EXs, MVBs and their carried molecules, are thought to
mainly involve into cancer cell proliferation, invasion and metastasis, and play a key
role in tumor progression [24]. Numerous studies found cancer cells can released much
more EXs than the normal cells derived. Tumor derived EXs usually contain special
molecules, such as the specific antigen on the surface of EXs, they can be served as a
potential biomarker for cancer diagnose and treatment. MiRs, as an important content
in EXs, are also focus on recently. Due to the different origins of microRNAs, some
microRNAs enrich in certain exosomes, it can be a novel biomarker in diseases
diagnosis and treatment.
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Ⅶ. CONCLUSION

In this study, EXs secreted from C6-Ceramide stimulated MM cells, which have a
high level of miR-29b, could inhibit the proliferation, migration, tube formation and
VEGFA expression of HUVECs. EXs derived microRNA-29b negatively regulated
the angiogenesis of ECs. MiR-29b inhibitor increases proliferation, migration, tube
formation and VEGFA expression of ECs with the effect of EXs released from MM
cells.
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